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Adenovirus early region 1A (E1A) possesses potent transforming activity when expressed in concert with activated ras or E1B genes
in in vitro tissue culture systems such as embryonic human retinal neuroepithelial cells or embryonic rodent epithelial and fibroblast
cells. Early region 1A has thus been used extensively and very effectively as a tool to determine the molecular mechanisms that
underlie the basis of cellular transformation. In this regard, roles for the E1A-binding proteins pRb, p107, p130, cyclic AMP response
element-binding protein (CBP)/p300, p400, TRRAP and CtBP in cellular transformation have been established. However, the
mechanisms by which E1A promotes transformation through interaction with these partner proteins are not fully delineated. In this
review, we focus on recent advances in our understanding of CBP/p300 function, particularly with regard to its relationship to
the anaphase-promoting complex/cyclosome E3 ubiquitin ligase, which has recently been shown to interact and affect the activity of
CBP/p300 through interaction domains that are evolutionarily conserved in E1A.
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ADENOVIRUS AS A TOOL FOR DISSECTING THE
MOLECULAR MECHANISMS OF CELLULAR
TRANSFORMATION
The adenoviruses are a family of small nonenveloped viruses with
linear double-stranded DNA genomes of about 35kbp. They infect
most animal species and cause a range of clinical diseases in
humans. Fifty-one human adenovirus (HAdV) serotypes have been
isolated to date and divided into six subgroups, termed A–F,
according to a variety of criteria (Benko et al, 2000). Forty years
ago, HAdV-12 was shown to induce tumours when injected into
newborn hamsters, providing the first evidence that a human virus
could be oncogenic (Trentin et al, 1962). Although only subgroup
A HAdVs, such as HAdV-12, efficiently induce tumours in rodents,
all HAdVs appear capable of cellular transformation in in vitro
tissue culture systems. The differential oncogenicity observed in
animals is attributed to the ability of the more oncogenic viruses to
evade the host immune response, as cells transformed by otherwise
nononcogenic serotypes will induce tumours in immunocompro-
mised animals (Gallimore and Turnell, 2001).
Expression of the leftmost adenoviral gene, termed early region
1A (E1A) is crucial for transformation and has been most
extensively characterised in HAdV-5. The HAdV-5 E1A gene
encodes two major proteins of 289 and 243 residues, which arise
from differential splicing of the same transcript and differ only by
the presence of an internal sequence of 46 amino acids in the larger
protein (Figure 1). Sequence comparisons of the largest E1A
proteins of several adenovirus serotypes identified four regions of
sequence conservation, designated conserved regions (CR) 1, 2, 3
and 4 (Avvakumov et al, 2002), which are important for many of
E1A’s biological activities (see below).
In infected human cells, E1A is essential for a productive viral
infection, although this can be bypassed using higher multiplicities
of infection (Berk, 2005). The effects of E1A can be considered to
be largely, if not completely, mediated by changes in transcription.
Early region 1A is the first viral gene expressed after infection and
is responsible for activating viral gene transcription. It also
reprogrammes host cell gene expression, forcing quiescent cells to
enter and pass through the cell cycle, and moreover, blocks cell
differentiation (Gallimore and Turnell, 2001; Frisch and Mymryk,
2002; Berk, 2005). HAdV infection of human cells usually results in
the death of the host cell and the release of progeny virus. Cell
death precludes the possibility of malignancies resulting from
human infection. For this reason, and probably others, adeno-
viruses are not generally thought to be a cause of human cancer. In
contrast to human cells, HAdV infection of rodent cells is
nonproductive. In this context, infection does not result in cell
death and E1A’s oncogenic properties become readily apparent.
Early region 1A can efficiently immortalise rodent cells or fully
transform them in cooperation with a second oncogene, such as
the adenovirus E1B gene or activated ras (Gallimore and Turnell,
2001; Frisch and Mymryk, 2002; Berk, 2005). Despite its clear
oncogenic properties, expression of E1A in previously transformed
cells has shown that it can, in certain circumstances, also function
as an antioncogene to suppress metastasis, angiogenesis and
tumorigenicity in vivo, trigger apoptosis, and induce differentia-
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Turnell, 2001; Frisch and Mymryk, 2002).
REQUIREMENT FOR CELLULAR E1A-BINDING
PROTEINS IN THE TRANSFORMATION PROCESS
The E1A proteins act by directly binding to cellular regulators that
play key roles in controlling gene expression and cell growth.
Although neither the crystal nor solution structure is known for
any of the E1A proteins, mutational analysis has clearly shown that
the E1A proteins are organised as a collection of independent
protein-binding modules that confer interaction with a number of
cellular proteins (Gallimore and Turnell, 2001; Frisch and
Mymryk, 2002; Berk, 2005). For example, E1A interacts with
the cellular transcriptional corepressor CtBP via the short motif
PxD/NLS (where x is variable) found in CR4 and binds the
transcriptional repressor and cell-cycle regulator pRb through the
core motif DLxCxE found in CR2. Moreover, E1A interaction with
the cyclic AMP response element-binding protein (CBP)/p300
acetyltransferases requires the motif FxD/ExxxL found in CR1.
Each of these sequences was originally identified within E1A, but
has since been found in numerous cellular proteins that also
interact with these targets. Presumably, these interaction motifs
have been hijacked by E1A from cellular genes via recombination
events, or the E1A gene has evolved independently, such that the
protein mimics cellular protein interaction surfaces in order to
provide selected functional advantages to E1A, and consequently
the virus.
Given these properties, E1A has been instrumental in the
identification of key cellular regulatory proteins involved in
transformation. The most notable of these is the tumour
suppressor pRb, which was the first E1A-binding protein to be
identified. Indeed, the identification of pRb as an E1A-binding
protein was the first demonstration of a physical link between an
oncogene and a tumour suppressor gene (Whyte et al, 1988).
Functionally, E1A binding to pRb activates host cell DNA synthesis
in baby rat kidney (BRK) cells through promoting the release of
the transcription factor E2F from pRb to activate transcription of
the viral E2A gene and a number of cellular S-phase-specific genes.
Mutational analyses have indicated that interference with the cell-
cycle regulatory functions of pRb is required for cellular
transformation by E1A (Gallimore and Turnell, 2001; Frisch and
Mymryk, 2002; Berk, 2005). The ability of E1A to bind and remodel
p400- and TRRAP- containing complexes through its N-terminal
region is also important in transformation (Gallimore and Turnell,
2001). The C-terminal CR4 domain of E1A also functions in the
transformation process, suppressing E1A/ras-mediated transfor-
mation, while enhancing E1A/E1B-mediated transformation
(Mymryk, 1996; Frisch and Mymryk, 2002). It has been postulated
that E1A interaction with CtBP is crucial for these activities. The
interaction of E1A with CtBP has also been shown to relieve
repression of cellular genes and promote mesenchymal to
epithelial transition (Grooteclaes and Frisch, 2000). The functions
of other C-terminal binding proteins in the transformation process
await further investigation.
INTERACTION OF E1A WITH CBP AND P300
The p300 protein was first identified through its specific
interaction with the N-terminal region and CR1 of E1A (Eckner
et al, 1994). Following characterisation of the p300 gene, it was
subsequently determined that E1A also binds the highly-related
CBP (Arany et al, 1995). Before the formal characterisation of CBP/
p300, however, the use of E1A mutants had established that the
interaction of E1A with these proteins was required for the
induction of DNA synthesis (S-phase entry) in BRK cells, although
S-phase could also be induced by a redundant pathway via
interaction with pRb (Howe et al, 1990). Early region 1A’s capacity
to induce mitosis required interaction with both pRb and CBP/
p300 (Howe and Bayley, 1992). The interaction of E1A with CBP/
p300 was also found to be necessary for E1A to transform primary
rodent cells in tissue culture, as E1A mutants lacking the capacity
to bind CBP/p300 were found to be transformation-defective
(Gallimore and Turnell, 2001; Frisch and Mymryk, 2002).
Surprisingly, little is known about the mechanism by which E1A
promotes cellular transformation through its interaction with CBP/
p300. To gain insight into this activity, we must consider the
properties of these two proteins. Cyclic AMP response element-
binding protein and p300 are two large, highly related lysine
acetyltransferases that function as transcriptional coactivators for
many sequence-specific transcription factors through the mod-
ification of chromatin (Goodman and Smolik, 2000; Iyer et al,
2004). The ability of CBP/p300 to activate transcription resides in
its capacity to acetylate the core histone proteins associated with
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Figure 1 Linear depiction of the HAdV-5 243R E1A protein. The regions conserved between serotypes are labelled as CR1, CR2 and CR4; amino-acid
ordinates depict CR boundaries. The domains required for the indicated E1A functions are indicated as black bars beneath the map. The location and
consensus sequences of binding motifs necessary for interaction with CBP/p300, pRb and CtBP are indicated, as are the general regions of E1A implicated in
binding to the specified cellular proteins. K239, the major acetylation site targeted by CBP/p300, is also depicted.
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conformation changes in chromatin and allows the recruitment of
auxiliary proteins to activated promoters. Cyclic AMP response
element-binding protein/p300 also have the capacity to acetylate
and regulate the activity of a variety of transcription factors
including p53, NF-kB and c-Myc. Acetylation in this context affects
both the ability of transcription factors to bind DNA, and also to
recruit other binding proteins (Goodman and Smolik, 2000). In
vitro models suggest that sequestration of CBP/p300 by E1A has
the general effect of repressing transcription by any factor that
utilises these acetyltransferases (Gallimore and Turnell, 2001).
However, whether E1A functions in vivo to specifically repress
CBP/p300 function during tumorigenesis is unknown. It is possible
that E1A could utilise CBP/p300 acetyltransferases during tumori-
genesis to promote an altered programme of gene expression.
Indeed, E1A residue K239 is a major target for CBP/p300
acetylation in vivo, and E1A associates with ‘active’ CBP/p300
acetyltransferases from transformed cells (AS Turnell, unpublished
data). Acetylation of E1A has been proposed to affect its
interaction with the corepressor CtBP, and alter its nuclear
localisation by disrupting E1A association with importin-a (Zhang
et al, 2000; Madison et al, 2002). It is not yet clear, however,
whether acetylation of E1A is required for transformation with
either Ras or E1B.
Consistent with the notion that acetyltransferase activity might
be required for E1A-mediated transformation, a model has
recently been proposed, which suggests that the ability of E1A to
induce S-phase depends upon its ability to specifically modulate
histone methylation/acetylation status (Ghosh and Harter, 2003).
In this case, ‘Tet-on’-inducible expression of E1A in G0 initially
remodels chromatin by facilitating the demethylation of K9 of
histone H3 and the release of repressor E2Fs, and subsequently
promotes transcriptional activation and hence G1–S progression
by promoting acetylation of K9 of histone H3 and the recruitment
of activator E2Fs (Ghosh and Harter, 2003). How this is achieved
mechanistically however, and the role played by specific demethy-
lases and acetylases in this instance requires further investigation.
Cyclic AMP response element-binding protein/p300 also possess
inherent E4 ubiquitin ligase activity, and kinetically enhance the
Mdm2-mediated ubiquitylation of p53 (Grossman et al, 2003).
Whether CBP/p300 facilitates the ubiquitylation of E1A, or whether
E1A regulates E4 ligase activity during transformation has not
been formally addressed. Interestingly, biallelic mutations in CBP
or p300 have been identified in certain human epithelial cancers
and reintroduction of wild-type p300 into at least some of these
cells suppresses growth (Iyer et al, 2004). Cyclic AMP response
element-binding protein haploinsufficiency in humans results in
Rubinstein–Taybi syndrome, which is not only typified by mental
retardation and physical deformities, but also an increased
incidence of some types of cancer. Based on these criteria, CBP
and p300 exhibit many of the hallmarks of classical tumour
suppressor genes (Goodman and Smolik, 2000; Iyer et al, 2004).
FUNCTION OF THE ANAPHASE-PROMOTING
COMPLEX/CYCLOSOME (APC/C) AND POTENTIAL
ROLE IN TUMORIGENESIS
The APC/C is a macromolecular E3 ubiquitin ligase that
coordinates the progression of eukaryotic cells through mitosis,
by the timely and selective targeting of protein substrates for 26S
proteasome-mediated degradation through ubiquitylation (Harper
et al, 2002; Peters, 2002). Anaphase-promoting complex/cyclosome
selectivity and activity is regulated in a spatially and temporally
coordinated manner through the recruitment of Cdc20 or Cdh1,
two closely related activators, to distinct phosphorylated-APC/C
species. The APC/C targets proteins for destruction through the
recognition of one or more loosely defined sequence motifs in the
protein substrate: the destruction (D) box, the KEN box or the
Aurora A-like (A) box (Harper et al, 2002; Peters, 2002). For
example, the protein levels of cyclin A and cyclin B1 are regulated
in a cell-cycle-specific manner by 26S proteasome-mediated
destruction dependent on such APC/C-targeting motifs.
As its name suggests, a primary function of the APC/C is to
promote sister-chromatid separation at the metaphase to anaphase
transition during mitosis. This is achieved mechanistically through
the targeted ubiquitylation and subsequent destruction of the
Separase inhibitor, Securin. Upon Securin degradation, Separase
cleaves the Cohesin complex component SCC1, which holds sister
chromatids together, allowing chromosome partitioning via the
mitotic spindle apparatus. The subsequent APC/C-mediated
degradation of cyclin B1 allows for mitotic exit and re-entry into
G1 (Harper et al, 2002; Peters, 2002).
Given the key role of the APC/C in coordinating mitosis, and
ensuring the fidelity of sister-chromatid separation, it might be
anticipated that de-regulation of APC/C function through muta-
tion may lead to genomic instability, the generation of aneuploid
daughter cells and cancer. Thus, the APC/C, components thereof,
or APC/C regulator proteins might possess inherent tumour
suppressor activity to protect against such events. Evidence that
individual APC/C components are mutated or deleted in human
cancers is scarce. One report suggests that there is a significant loss
of APC7 protein expression in ductal breast carcinomas displaying
malignant characteristics (Park et al, 2005), although how this loss
of APC7 affects the function of the holoenzyme is unclear. In
addition, analysis of APC/C genes from colorectal cancer cell lines
suggests that APC4, APC6 and APC8 are susceptible to mutation,
whereas the same study identified one colon tumour from a cohort
of 22 (Duke stage not specified) with a mutation in APC8 (Wang
et al, 2003). It is obvious that more extensive analyses using
tumour material is needed to establish if the APC/C is targeted
directly during human tumorigenesis.
Perhaps, a more accurate picture of whether APC/C function is
de-regulated during tumorigenesis is a consideration of how
aberrant expression of APC/C substrates and APC/C regulators
affects cell-cycle progression and ploidy status. In this regard, the
overexpression of a number of APC/C substrates can promote
genomic instability. For instance, overexpression of the APC/C
substrate Securin in mammalian cells promotes cellular transfor-
mation through aneuploidy, and moreover, is found specifically
overexpressed in a number of human tumours (McCabe and
Heaney, 2003). Similarly, overexpression of the APC/C substrate
Skp2, an integral component of the SCF ubiquitin ligases that
coordinate S-phase entry through the timely destruction of the
p21
CIP1/WAF1 and p27
KIP1 cyclin-dependent kinase inhibitors, can
promote untimely entry into the S-phase and cell-cycle progres-
sion; Skp2 overexpression is observed in a number of human
cancers with poor prognosis (Nakayama and Nakayama, 2005).
Stabilisation of APC/C inhibitors such as Emi1 can also result in
genetic instability, through interference with the centrosome
duplication cycle (Guardavaccaro et al, 2003; Margottin-Goguet
et al, 2003). Similar arguments for other APC/C substrates and
regulators could also be made, but it is apparent from these
examples that the de-regulation of the APC/C might play an
important role in promoting genomic instability and consequently
tumorigenesis.
RELATIONSHIP BETWEEN CBP/P300 AND THE APC/C
Interestingly, our studies of cellular transformation by E1A
identified a previously unrecognised functional link between the
APC/C and CBP/p300 (Turnell et al, 2005). Specifically, we found
that the APC/C components, APC5 and APC7, possess within their
primary sequence bona fide CBP/p300 protein–protein interaction
domains that are homologous to E1A (see Figure 1). Significantly,
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components of the APC/C holoenzyme, stimulated p300 acetyl-
transferase activity, and hence the transcriptional activity of p300,
by enhancing autoacetylation of p300-K1499 in an ubiquitylation-
independent manner. The ability of these APC/C subunits to
regulate CBP/p300 transcriptional activity suggests that the APC/C
might also regulate progression of cells through the G1-phase of
the cell cycle by coordinating CBP/p300-dependent gene expres-
sion programmes that prevent, or allow entry into the S-phase
(Figure 2). In this context, the APC/C might also regulate CBP/
p300-dependent differentiation pathways. Significantly, we estab-
lished a role for the APC/C in G1 arrest by determining that
knockdown of APC5 or APC7 by RNA interference (RNAi) affected
the ability of CBP/p300 to potentiate p21
CIP1/WAF1 expression in
primary human fibroblasts exposed to ionising radiation; the APC/
C associates directly with the p21
CIP1/WAF1 promoter region. We
also established a potential role for the APC/C in the S-phase entry
by determining that both APC5 and APC7 can potentiate the CBP/
p300-dependent activation of the transcription factor E2F-1; the
APC/C associates directly with the E2F-1-regulated gene promoter
CDC6. Given these findings, it appears that the function of the
APC/C is not only important in driving mitosis but also in
progression of cells through G1 into the S-phase (Figure 2). As the
APC/C is a key regulator of mitotic progression, we also
investigated potential roles for CBP/p300 in mitosis. Through the
use of selective RNAi treatment, we determined that CBP functions
to regulate mitotic exit (Figure 2). In this regard, it is our belief
that inherent CBP E4 activity enhances APC/C-directed E3
ubiquitylation of substrates such as cyclin B1, through binding
the APC/C via APC5 and/or APC7 (Turnell et al, 2005).
E1A PROMOTES CELLULAR TRANSFORMATION BY
TARGETING CBP/P300–APC/C COMPLEXES
Given the high degree of cooperation between the APC/C and CBP/
p300 in regulating transcription and cell-cycle progression, we
investigated whether E1A promoted cellular transformation by
‘targeting’ APC/C–CBP/p300 complexes during the transformation
process (Turnell et al, 2005). We showed that exogenous
expression of wild-type APC5 or APC7 suppressed the ability of
E1A to cooperate with E1B or activated-Ras in the transformation
of primary rat embryo fibroblasts, whereas the expression of APC5
or APC7 mutants unable to bind CBP/p300 did not suppress E1A-
induced transformation. These data clearly established CBP/p300
as a major E1A ‘target’ during transformation. Moreover, in
agreement with our earlier proposal, they suggested that APC5 and
APC7 might possess inherent tumour suppressor activity. To
address this possibility directly, we utilised the R2G E1A mutant
that does not bind CBP/p300, and which under normal circum-
stances is transformation defective. We hypothesised that if wild-
type E1A targeted APC/C function directly during transformation
through binding CBP/p300, then it might be possible to restore
transformation potential to a transformation-defective E1A
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Figure 2 Role of APC/C–CBP/p300 complexes in transcription and cell-cycle control. (A(a)) Transcription and acetylation. Cyclic AMP response
element-binding protein/p300 function as transcriptional coactivators for sequence-specific DNA-binding transcription factors. These enzymes acetylate
histones to alter chromatin accessibility. Cyclic AMP response element-binding protein/p300 also acetylate transcription factors to regulate their activity.
Interaction with E1A or the APC/C potentially interferes and/or retargets this activity and E1A is itself a substrate for acetylation. Anaphase-promoting
complex5 and/or APC7, as components of the APC/C holoenzyme, interact with CBP/p300 to stimulate inherent CBP/p300 acetyltransferase activity, and
CBP/p300-dependent transcriptional activity. Early region 1A might disrupt or mimic APC/C function in this regard through its interaction with CBP/p300.
(A(b)) Transcription and ubiquitylation. The recruitment of the APC/C to target promoters could potentially regulate CBP/p300 function by promoting
CBP/p300 ubiquitylation. The ubiquitylation of the CBP/p300 in this instance could directly affect CBP/p300 acetyltransferase activity, and/or affect CBP/p300
interaction with other proteins, and/or promote proteasomal-mediated degradation of CBP/p300. Early region 1A could interfere with APC/C functioni n
this regard by binding directly to CBP/p300. (B) Mitosis. The APC/C complex ubiquitylates cell-cycle regulatory proteins and targets them for proteasomal
degradation. Cyclic AMP response element-binding protein functions as an E4 ligase in this regard. Whether acetylation of the APC/C by CBP/p300 regulates
APC/C E3 ligase activity in this regard requires further investigation. We propose that E1A might regulate mitotic progression and/or promote genomic
instability through interfering directly with APC/C function in mitosis through its ability to bind CBP/p300. Ac, acetylated-residues; pUb, polyubiquitylation;
5, 7 and 11 refer to APC/C subunits. APC11 is the functional ubiquitin ligase. P, phosphorylated residues.
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function through the selective knockdown of APC5 and/or APC7
protein levels by RNAi. In agreement with our hypothesis, the
transformation capacity of R2G E1A, but not wild-type E1A, was
increased upon knockdown of APC5 and/or APC7 gene expression
in primary rat embryo fibroblasts. These studies clearly demon-
strated that E1A targets CBP/p300 during transformation to
regulate specifically the APC/C.
In light of these observations, we propose that E1A-mediated
perturbation/re-orchestration of the normal function of CBP/
p300–APC/C complexes is a key event in the induction of cellular
transformation (Turnell et al, 2005). We suggest that E1A regulates
the ability of CBP/p300–APC/C complexes to induce S-phase
entry, and promote mitosis. Mechanistically, E1A may induce
cellular DNA synthesis by inhibiting the CBP/p300–APC/C-
dependent transcriptional activation of genes involved in G1 arrest
(e.g. p21
CIP1/WAF1), and utilising distinct CBP/p300 complexes,
potentially in the absence of the APC/C, to induce genes that
promote progression into the S-phase. Early region 1A interaction
with CBP would also de-regulate the highly coordinated, spatial
and temporal activities of the APC/C during mitosis. Here, we
suggest that de-regulation of the APC/C by E1A would lead to
aberrant mitoses through the direct modulation of CBP-APC/C
ubiquitin ligase activity, and potentially by affecting APC/C
responses to spindle checkpoint programmes. In consideration
of E1A’s capacity to target CBP/p300–APC/C complexes during
the transformation process, it is conceivable that E1A could also,
in a spatially and/or temporally coordinated manner, selectively
disrupt APC5–CBP/p300 and/or APC7–CBP/p300 complexes in
the context of the APC/C holoenzyme to inhibit some APC/C–
CBP/p300 complexes, yet allow for the specific ‘activation’ of
others.
A role for E1A in promoting genomic instability is well
established. Early studies with HAdV determined that infection
of permissive and nonpermissive cells caused both random and
nonrandom host cell chromosome aberrations. Aberrant mitoses
were also observed in Ad-infected rodent cells, and Ad-induced
tumorigenesis was found to be associated with both aneuploidy
and polyploidy (see Murray et al, 1982 and references therein).
Significantly, HAdV-induced genomic instability is predominantly
due to E1A expression (Caporossi and Bacchetti, 1990). More
recent studies suggest that E1A can induce genomic instability, in
part, through its ability to bind Ran, interfere with the centrosome
duplication cycle and promote centrosome amplification (De Luca
et al, 2003). Whether E1A can promote genomic instability
through the de-regulation of the APC/C awaits further investi-
gation.
FUTURE PERSPECTIVES
Although it is apparent that the functions of CBP/p300 and the
APC/C are intimately linked, there are many questions regarding
their function in transcription and cell-cycle progression that
remain to be addressed. Given the enzymatic properties of CBP/
p300 and the APC/C, it will be important to define molecular
crosstalk between the two complexes. Specifically, does CBP/p300
regulate APC/C function through acetylation of APC/C compo-
nents, or APC/C regulators? Similarly, as the APC/C is implicated
in controlling the protein levels of CBP/p300, it will be important
to establish whether the APC/C-directed ubiquitylation of CBP/
p300 modulates their ability to function as coactivators in
transcription. In this regard, it would be tempting to speculate
that in a temporally coordinated manner, the APC/C regulates
CBP/p300 function initially through modulation of acetyltransfer-
ase activity by direct interaction, and subsequently ubiquitylates
CBP/p300 in order to promote other CBP/p300 functions and/or to
regulate its proteasomal-mediated destruction. Moreover, as CBP/
p300 acetyltransferases and the APC/C E3 ubiquitin ligase both
specifically target lysine residues, it will be of particular
importance to establish whether there is a cell-cycle-regulated
hierarchical sequence of acetylation and ubiquitylation events that
determine their function.
In addition, there are other levels of complexity that need to be
examined. Particularly, why do both CBP and p300 interact with
the APC/C? Presumably, CBP–APC/C complexes and p300–APC/C
complexes perform distinct functions during the cell cycle. Indeed,
given that it is CBP that functions solely with the APC/C in mitosis,
it is unlikely that these proteins operate redundantly. Moreover,
why should CBP and p300 bind independently to two different
APC/C subunits? Presumably, this reflects the differential activities
of APC5 and APC7 in transcription and cell-cycle control and
might suggest the existence of discrete subpopulations of APC/C
performing distinct functions. Alternatively, this might suggest the
existence of APC/C subcomplexes with distinct subunit composi-
tion. Discerning the potential differential abilities of E1A to
modulate these activities and hence functions will be fundamental
in establishing how E1A promotes cellular transformation.
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